EQS-News: Lonza Completes Divestment of Specialty Ingredients Business

Basel, Switzerland, 2 July 2021 - Lonza announced today the completion of the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion.

Albert M. Baehny, Chairman, Lonza commented: 'Since announcing our intention to divest the Specialty Ingredients business, we have made significant progress in consolidating our new structure and identity and refining our focus as a pure-play partner to the healthcare industry. As the divestment of the Specialty Ingredients business completes, at Lonza we have an opportunity to consolidate our identity and redouble our focus on long-term growth while delivering value for our customers, employees and shareholders.

'I wish to thank the leadership teams and all employees in the Specialty Ingredients business for their continuing dedication and professionalism during the transition period. We remain close neighbors with the Specialty Ingredients business at some of our sites, so we look forward to continuing to collaborate with the new company and wish it much success under its new ownership.'

The agreement between both parties was previously announced on 8 February 2021.

News release (PDF)

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com

Follow @Lonza on LinkedIn

Follow @LonzaGroup on Twitter

Lonza Contact Details

Media / Communications Team
[email protected]

Dirk Oehlers

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540
[email protected]

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.


Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Privacy Policy link

To immediately delete all the data